RxDoctor Payments Data

Gabriel Ymalay, MD

Internal Medicine · Independence, KYNPI 1073957528

Payments from drug & device makers

$8,231in general payments, 2019–2025

Across 496 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$733
  • GSK$510
  • Amgen$509
  • Pfizer$465
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,231 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$41,125
Medicare patients
151
Services billed
1,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$48,286
EliquisApixaban33$37,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$37,853
TrulicityDulaglutide16$27,039
JanuviaSitagliptin Phosphate17$25,578
MounjaroTirzepatide22$24,431
FarxigaDapagliflozin Propanediol21$23,334
XareltoRivaroxaban20$20,523
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$17,344
JanumetSitagliptin Phos/Metformin Hcl19$11,832
Repatha SureclickEvolocumab13$8,244
Ambien CrZolpidem Tartrate11$6,741
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$3,271
Atorvastatin Calcium295$2,667
Gabapentin142$2,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$440$51,47038 claims
Novo NordiskOzempic$1,049$48,28636 claims
PfizerEliquis$465$37,85533 claims
GSKTrelegy Ellipta$510$37,85325 claims
MerckJanuvia, Janumet$60$37,40936 claims
AstraZenecaFarxiga$733$23,33421 claims
Johnson & JohnsonXarelto$166$20,52320 claims
AbbVieSynthroid$1,803$1,24232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Independence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →